Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffit Hassan

Showing results (21-30 of 150) with videos related to

Pageof 15
Sort By:
Cancer|February 23, 2021
Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapiesZishuo I Hu, Azam Ghafoor, Manjistha Sengupta, et al.
Molecular Cancer Therapeutics|February 22, 2012
Mesothelin-targeted agents in clinical trials and in preclinical developmentRonan J Kelly, Elad Sharon, Ira Pastan, et al.
Anticancer Research|July 28, 2004
Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomasQian Li, Claire F Verschraegen, John Mendoza, et al.
Oncotarget|November 21, 2017
Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathwayXiu-Fen Liu, Qi Zhou, Raffit Hassan, et al.
Journal of Cancer|April 12, 2011
In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude miceMingqian Feng, Jingli Zhang, Miriam Anver, et al.
Annual Review of Medicine|October 25, 2006
Immunotoxin treatment of cancerIra Pastan, Raffit Hassan, David J FitzGerald, et al.
Nature Reviews. Cancer|June 24, 2006
Immunotoxin therapy of cancerIra Pastan, Raffit Hassan, David J Fitzgerald, et al.
Annals of the American Thoracic Society|August 1, 2014
Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic reviewAndrew C Miller, Markku Miettinen, David S Schrump, et al.
Clinical Lung Cancer|May 9, 2026
Prognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal MesotheliomaKeval Yerigeri, Manjistha Sengupta, Jingli Zhang, et al.
Cancer Research|July 22, 2011
Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin sheddingYujian Zhang, Oleg Chertov, Jingli Zhang, et al.
Pageof 15

Showing results (21-30 of 150) with videos related to

Sort By:
Pageof 15
Cancer|February 23, 2021
Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapiesZishuo I Hu, Azam Ghafoor, Manjistha Sengupta, et al.
Molecular Cancer Therapeutics|February 22, 2012
Mesothelin-targeted agents in clinical trials and in preclinical developmentRonan J Kelly, Elad Sharon, Ira Pastan, et al.
Anticancer Research|July 28, 2004
Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomasQian Li, Claire F Verschraegen, John Mendoza, et al.
Oncotarget|November 21, 2017
Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathwayXiu-Fen Liu, Qi Zhou, Raffit Hassan, et al.
Journal of Cancer|April 12, 2011
In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude miceMingqian Feng, Jingli Zhang, Miriam Anver, et al.
Annual Review of Medicine|October 25, 2006
Immunotoxin treatment of cancerIra Pastan, Raffit Hassan, David J FitzGerald, et al.
Nature Reviews. Cancer|June 24, 2006
Immunotoxin therapy of cancerIra Pastan, Raffit Hassan, David J Fitzgerald, et al.
Annals of the American Thoracic Society|August 1, 2014
Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic reviewAndrew C Miller, Markku Miettinen, David S Schrump, et al.
Clinical Lung Cancer|May 9, 2026
Prognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal MesotheliomaKeval Yerigeri, Manjistha Sengupta, Jingli Zhang, et al.
Cancer Research|July 22, 2011
Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin sheddingYujian Zhang, Oleg Chertov, Jingli Zhang, et al.
Pageof 15